← Back to Search

Treatment for Juvenile Idiopathic Arthritis (UCAN CAN-DU Trial)

N/A
Recruiting
Led By Bas Vastert, MD, PhD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Summary

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

Eligible Conditions
  • Juvenile Idiopathic Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluate biological outcomes associated with the de-prescribing of therapeutic agents in children with JIA
Evaluate biological outcomes associated with the use of therapeutic agents in children with JIA
Evaluate clinical outcomes associated with the de-prescribing of therapeutic agents in children with JIA
+9 more

Find a Location

Who is running the clinical trial?

Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,373 Previous Clinical Trials
26,515,142 Total Patients Enrolled
Genome CanadaOTHER
15 Previous Clinical Trials
27,570 Total Patients Enrolled
The Hospital for Sick ChildrenLead Sponsor
704 Previous Clinical Trials
6,952,777 Total Patients Enrolled
~311 spots leftby Mar 2025